Tie2 and Eph receptor tyrosine kinase activation and signaling

Cold Spring Harbor Perspectives in Biology

Volumn 6, Issue 3, 2014, Pages

  Barton, William A ^a   Dalton, Annamarie C ^a   Seegar, Tom C M ^a   Himanen, Juha P ^b   Nikolov, Dimitar B ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; EPHRIN RECEPTOR; LIGAND;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVATION; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ANGIOPOIETINS; BINDING SITES; ENZYME ACTIVATION; LIGANDS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, TIE-2; RECEPTORS, EPH FAMILY; SIGNAL TRANSDUCTION;

EID: 84897584960     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a009142     Document Type: Article

References (105)

1. Abengozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, Olmeda D, Marenchino M, Canamero M, Ortega S, Megias D, et al. 2012. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 119: 4565-4576.
2. Adams RH, Alitalo K. 2007. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev 8: 464-478.
3. Artemenko EO, Egorova NS, Arseniev AS, Feofanov AV. 2008. Transmembrane domain of EphA1 receptor forms dimers in membrane-like environment. Biochim Biophys Acta 1778: 2361-2367.
4. Barton WA, Tzvetkova D, Nikolov DB. 2005. Structure of the angiopoietin-2 receptor binding domain and identification of surfaces involved in Tie2 recognition. Structure 13: 825-832.
5. Barton WA, Tzvetkova-Robev D, Miranda EP, Kolev MV, Rajashankar KR, Himanen JP, Nikolov DB. 2006. Crystal structures of the Tie2 receptor ectodomain and the angiopoietin- 2-Tie2 complex. Nat Struct Mol Biol 13: 524-532.
6. Bocharov EV, Mayzel ML, Volynsky PE, Goncharuk MV, Ermolyuk YS, Schulga AA, Artemenko EO, Efremov RG, Arseniev AS. 2008. Spatial structure and pH-dependent conformational diversity of dimeric transmembrane domain of the receptor tyrosine kinase EphA1. J Biol Chem 283: 29385-29395.
7. Bocharov EV, Mayzel ML, Volynsky PE, Mineev KS, Tkach EN, Ermolyuk YS, Schulga AA, Efremov RG, Arseniev AS. 2010. Left-handed dimer of EphA2 transmembrane domain:Helix packing diversity among receptor tyrosine kinases. Biophys J 98: 881-889.
8. Bocharov EV, Mineev KS, Goncharuk MV, Arseniev AS. 2012. Structural and thermodynamic insight into the process of "weak" dimerization of the ErbB4 transmembrane domain by solution NMR. Biochim Biophys Acta 1818: 2158-2170.
9. Bowden TA, Aricescu AR, Nettleship JE, Siebold C, Rahman-Huq N, Owens RJ, Stuart DI, Jones EY. 2009. Structural plasticity of eph receptor A4 facilitates cross-class ephrin signaling. Structure 17: 1386-1397.
10. Chen J, Zhuang G, Frieden L, Debinski W. 2008. Eph receptors and Ephrins in cancer: Common themes and controversies. Cancer Res 68: 10031-10033.
11. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
12. Choi Y, Syeda F, Walker JR, Finerty PJ Jr, Cuerrier D, Wojciechowski A, Liu Q, Dhe-Paganon S, Gray NS. 2009. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 19: 4467-4470.
13. Chrencik JE, Brooun A, Recht MI, Kraus ML, Koolpe M, Kolatkar AR, Bruce RH, Martiny-Baron G, Widmer H, Pasquale EB, et al. 2006. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure 14: 321-330.
14. Chrencik JE, Brooun A, Recht MI, Nicola G, Davis LK, Abagyan R, Widmer H, Pasquale EB, Kuhn P. 2007. Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem 282: 36505-36513.
15. Cowan CA, Henkemeyer M. 2001. The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature 413: 174-179.
16. Cowan CA, Henkemeyer M. 2002. Ephrins in reverse, park and drive. Trends Cell Biol 12: 339-346.
17. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, et al. 1996. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169.
18. Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, Xu A, Leidich R, Radziejewska E, Rafique A, et al. 2003. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 10: 38-44.
19. Davis TL, Walker JR, Loppnau P, Butler-Cole C, Allali-Hassani A, Dhe-Paganon S. 2008. Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3). Structure 16: 873-884.
20. Day B, To C, Himanen JP, Smith FM, Nikolov DB, Boyd AW, Lackmann M. 2005. Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3. J Biol Chem 280: 26526-26532.
21. Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, Deutsch U, Martiny-Baron G, Marme D, Augustin HG. 2003. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 278: 1721-1727.
22. Flanagan JG, Vanderhaeghen P. 1998. The ephrins and Eph receptors in neural development. Annu Rev Neurosci 21: 309-345.
23. Furdui CM, Lew ED, Schlessinger J, Anderson KS. 2006. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell 21: 711-717.
24. Giorgio C, Hassan Mohamed I, Flammini L, Barocelli E, Incerti M, Lodola A, Tognolini M. 2011. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PloS ONE 6: e18128.
25. Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, Vogt T. 2004. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50: 490-499.
26. Hansen TM, Singh H, Tahir TA, Brindle NP. 2010. Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface. Cell Signal 22: 527-532.
27. Hattori M, Osterfield M, Flanagan JG. 2000. Regulated cleavage of a contact-mediated axon repellent. Science 289: 1360-1365.
28. He L, Hoffmann AR, Serrano C, Hristova K, Wimley WC. 2011. High-throughput selection of transmembrane sequences that enhance receptor tyrosine kinase activation. J Mol Biol 412: 43-54.
29. Himanen JP. 2012. Ectodomain structures of Eph receptors. Semin Cell Dev Biol 23: 35-42.
30. Himanen JP, Nikolov DB. 2002. Purification, crystallization and preliminary characterization of an Eph-B2/ ephrin-B2 complex. Acta Crystallogr D Biol Crystallogr 58: 533-535.
31. Himanen JP, Rajashankar KR, Lackmann M, Cowan CA, Henkemeyer M, Nikolov DB. 2001. Crystal structure of an Eph receptor-ephrin complex. Nature 414: 933-938.
32. Himanen JP, Saha N, Nikolov DB. 2007. Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol 19: 534-542.
33. Himanen JP, Goldgur Y, Miao H, Myshkin E, Guo H, Buck M, Nguyen M, Rajashankar KR, Wang B, Nikolov DB. 2009. Ligand recognition by A-class Eph receptors: Crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBORep 10: 722-728.
34. Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, Rajashankar KR, Mensinga A, Lackmann M, Nikolov DB, et al. 2010. Architecture of Eph receptor clusters. Proc Natl Acad Sci 107: 10860-10865.
35. Huang L, Turck CW, Rao P, Peters KG. 1995. GRB2 and SHPTP2: Potentially important endothelial signaling molecules downstream of the TEK/TIE2 receptor tyrosine kinase. Oncogene 11: 2097-2103.
36. Huang H, Bhat A, Woodnutt G, Lappe R. 2010. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10: 575-585.
37. Hubbard SR. 2004. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev MolCell Biol 5: 464-471.
38. Hubbard SR, Miller WT. 2007. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 19: 117-123.
39. Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M, Nikolov DB. 2005. Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123: 291-304.
40. Janes PW, Wimmer-Kleikamp SH, Frangakis AS, Treble K, Griesshaber B, Sabet O, Grabenbauer M, Ting AY, Saftig P, Bastiaens PI, et al. 2009. Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10. PLoS Biol 7: e1000215.
41. Janes PW, Griesshaber B, Atapattu L, Nievergall E, Hii LL, Mensinga A, Chheang C, Day BW, Boyd AW, Bastiaens PI, et al. 2011. Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. J Cell Biol 195: 1033-1045.
42. Janes PW, Nievergall E, Lackmann M. 2012. Concepts and consequences of Eph receptor clustering. Semin Cell Dev Biol 23: 43-50.
43. Jones N, Chen SH, Sturk C, Master Z, Tran J, Kerbel RS, Dumont DJ. 2003. Aunique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Mol Cell Biol 23: 2658-2668.
44. Klein R. 2001. Excitatory Eph receptors and adhesive ephrin ligands. Curr Opin Cell Biol 13: 196-203.
45. Klein R. 2009. Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat Neurosci 12: 15-20.
46. Kontos CD, Cha EH, York JD, Peters KG. 2002. The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis. Mol Cell Biol 22: 1704-1713.
47. Koolpe M, Dail M, Pasquale EB. 2002. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 277: 46974-46979.
48. Labrador JP, Brambilla R, Klein R. 1997. The N-terminal globular domain of Eph receptors is sufficient for ligand binding and receptor signaling. EMBO J 16: 3889-3897.
49. Lackmann M, Boyd AW. 2008. Eph, a protein family coming of age: more confusion, insight, or complexity? Sci Signal 1: pre2.
50. Lamberto I, Qin H, Noberini R, Premkumar L, Bourgin C, Riedl SJ, Song J, Pasquale EB. 2012. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor. Biochem J 445: 47-56.
51. Lauterbach J, Klein R. 2006. Release of full-length EphB2 receptors from hippocampal neurons to cocultured glial cells. J Neurosci 26: 11575-11581.
52. Lee HS, Daar IO. 2009. EphrinB reverse signaling in cell-cell adhesion: Is it just par for the course? Cell Adh Migr 3: 250-255.
53. Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
54. Li E, Hristova K. 2006. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 45: 6241-6251.
55. Li E, Hristova K. 2010. Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics. Cell Adh Migr 4: 249-254.
56. Li E, You M, Hristova K. 2005. Sodium dodecyl sulfatepolyacrylamide gel electrophoresis and forster resonance energy transfer suggest weak interactions between fibroblast growth factor receptor 3 (FGFR3) transmembrane domains in the absence of extracellular domains and ligands. Biochemistry 44: 352-360.
57. Lisabeth EM, Falivelli G, Pasquale EB. 2013. Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol 5: a009159.
58. Macdonald PR, Progias P, Ciani B, Patel S, Mayer U, Steinmetz MO, Kammerer RA. 2006. Structure of the extracellular domain of Tie receptor tyrosine kinases and localization of the angiopoietin-binding epitope. J Biol Chem 281: 28408-28414.
59. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. 1997. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
60. Marler KJ, Becker-Barroso E, Martinez A, Llovera M, Wentzel C, Poopalasundaram S, Hindges R, Soriano E, Comella J, Drescher U. 2008. A TrkB/EphrinA interaction controls retinal axon branching and synaptogenesis. J Neurosci 28: 12700-12712.
61. Marston DJ, Dickinson S, Nobes CD. 2003. Rac-dependent trans-endocytosis of ephrinBs regulates Eph-ephrin contact repulsion. Nat Cell Biol 5: 879-888.
62. Master Z, Jones N, Tran J, Jones J, Kerbel RS, Dumont DJ. 2001. Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak. EMBO J 20: 5919-5928.
63. Mendrola JM, Berger MB, King MC, Lemmon MA. 2002. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem 277: 4704-4712.
64. Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z, Pasquale EB. 2010. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry 49: 6687-6695.
65. Moriki T, Maruyama H, Maruyama IN. 2001. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol 311: 1011-1026.
66. Nievergall E, Janes PW, Stegmayer C, Vail ME, Haj FG, Teng SW, Neel BG, Bastiaens PI, Lackmann M. 2010. PTP1B regulates Eph receptor function and trafficking. J Cell Biol 191: 1189-1203.
67. Niu XL, Peters KG, Kontos CD. 2002. Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism. J Biol Chem 277: 31768-31773.
68. Noberini R, Koolpe M, Peddibhotla S, Dahl R, Su Y, Cosford ND, Roth GP, Pasquale EB. 2008. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 283: 29461-29472.
69. Noberini R, Koolpe M, Lamberto I, Pasquale EB. 2012a. Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols. Pharmacol Rese 66: 363-373.
70. Noberini R, Lamberto I, Pasquale EB. 2012b. Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin Cell Dev Biol 23: 51-57.
71. Noblitt LW, Bangari DS, Shukla S, Mohammed S, Mittal SK. 2005. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther 12: 46-53.
72. Nowakowski J, Cronin CN, McRee DE, Knuth MW, Nelson CG, Pavletich NP, Rogers J, Sang BC, Scheibe DN, Swanson RV, et al. 2002. Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure 10: 1659-1667.
73. Ottensmeyer FP, Beniac DR, Luo RZ, Yip CC. 2000. Mechanism of transmembrane signaling: Insulin binding and the insulin receptor. Biochemistry 39: 12103-12112.
74. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC, Sessa WC. 2000. Angiopoietin- 1 inhibits endothelial cell apoptosis via the Akt/ survivin pathway. J Biol Chem 275: 9102-9105.
75. Pasquale EB. 2008. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133: 38-52.
76. Pasquale EB. 2010. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180.
77. Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop GP, Hsieh JT, Page P, Liu L, Lindner DJ, et al. 2012. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro prostate cancer metastasis in vivo. PloS ONE 7: e42120.
78. Qin H, Shi J, Noberini R, Pasquale EB, Song J. 2008. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin- binding channel of the EphA4 receptor. J Biol Chem 283: 29473-29484.
79. Qin H, Noberini R, Huan X, Shi J, Pasquale EB, Song J. 2010. Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity. J Biol Chem 285: 644-654.
80. Qin H, Lim L, Song J. 2012. Protein dynamics at Eph receptor- ligand interfaces as revealed by crystallography, NMR and MD simulations. BMC Biophys 5: 2.
81. Ramsauer M, D'Amore PA. 2002. Getting Tie(2)d up in angiogenesis. J Clin Invest 110: 1615-1617.
82. Robinson D, He F, Pretlow T, Kung HJ. 1996. A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci 93: 5958-5962.
83. Schlessinger J. 2003. Signal transduction. Autoinhibition control. Science 300: 750-752.
84. Seegar TC, Eller B, Tzvetkova-Robev D, Kolev MV, Henderson SC, Nikolov DB, Barton WA. 2010. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 37: 643-655.
85. Seiradake E, Harlos K, Sutton G, Aricescu AR, Jones EY. 2010. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat Struct Mol Biol 17: 398-402.
86. Shewchuk LM, Hassell AM, Ellis B, Holmes WD, Davis R, Horne EL, Kadwell SH, McKee DD, Moore JT. 2000. Structure of the Tie2 RTK domain: Self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure 8: 1105-1113.
87. Shintani T, Ihara M, Sakuta H, Takahashi H, Watakabe I, Noda M. 2006. Eph receptors are negatively controlled by protein tyrosine phosphatase receptor typeO. NatNeurosci 9: 761-769.
88. Singla N, Himanen JP, Muir TW, Nikolov DB. 2008. Toward the semisynthesis of multidomain transmembrane receptors: Modification of Eph tyrosine kinases. Protein Sci 17: 1740-1747.
89. Singla N, Erdjument-Bromage H, Himanen JP, Muir TW, Nikolov DB. 2011. A semisynthetic Eph receptor tyrosine kinase provides insight into ligand-induced kinase activation. Chem Biol 18: 361-371.
90. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
91. Song J, Vranken W, Xu P, Gingras R, Noyce RS, Yu Z, Shen SH, Ni F. 2002. Solution structure and backbone dynamics of the functional cytoplasmic subdomain of human ephrin B2, a cell-surface ligand with bidirectional signaling properties. Biochemistry 41: 10942-10949.
92. Stamos J, Sliwkowski MX, Eigenbrot C. 2002. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 77: 46265-46272.
93. Sundberg EJ. 2009. Structural basis of antibody-antigen interactions. Methods Mol Biol 524: 23-36.
94. Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, et al. 1999. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci 96: 1904-1909.
95. Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, Brechbiel M, Boyd AW, Scott AM, et al. 2005. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: Potential as EphA3-specific tumor- targeting reagents. Cancer Res 65: 6745-6754.
96. Volynsky PE, Mineeva EA, Goncharuk MV, Ermolyuk YS, Arseniev AS, Efremov RG. 2010. Computer simulations and modeling-assisted ToxR screening in deciphering 3D structures of transmembrane alpha-helical dimers: Ephrin receptor A1. Phys Biol 7: 16014.
97. Wang B. 2011. Cancer cells exploit the Eph-ephrin system to promote invasion and metastasis: Tales of unwitting partners. Sci Signal 4: e28.
98. Ward NL, Dumont DJ. 2002. The angiopoietins and Tie2/ Tek: Adding to the complexity of cardiovascular development. Semin Cell Dev Biol 13: 19-27.
99. Wiesmann C, Muller YA, de Vos AM. 2000. Ligand-binding sites in Ig-like domains of receptor tyrosine kinases. JMol Med (Berl) 78: 247-260.
100. Wiesner S, Wybenga-Groot LE, Warner N, Lin H, Pawson T, Forman-Kay JD, Sicheri F. 2006. A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases. EMBO J 25: 4686-4696.
101. Wimmer-Kleikamp SH, Janes PW, Squire A, Bastiaens PI, Lackmann M. 2004. Recruitment of Eph receptors into signaling clusters does not require ephrin contact. J Cell Biol 164: 661-666.
102. Wimmer-Kleikamp SH, Nievergall E, Gegenbauer K, Adikari S, Mansour M, Yeadon T, Boyd AW, Patani NR, Lackmann M. 2008. Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood 112: 721-732.
103. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. 2001. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106: 745-757.
104. Yu X, Seegar TCM, Dalton AC, Tzvetkova-Robev D, Goldgur Y, Nikolov DB, Barton WA. 2013. Structural basis for angiopoietin-1 mediated signaling initiation. Proc Natl Acad Sci 110: 7205-7210.
105. Zimmer M, Palmer A, Kohler J, Klein R. 2003. EphB-ephrinB bi-directional endocytosis terminates adhesion allowing contact mediated repulsion. Nat Cell Biol 5: 869-878.